TREATMENT OF INTERVERTEBRAL DISC DEGENERATION USING HUMAN UMBILICAL CORD TISSUE-DERIVED CELLS

• US 20090169597A1
• Filed: 12/17/2008
• Published: 07/02/2009
• Est. Priority Date: 12/27/2007
• Status: Abandoned Application

• Current Assignee: Depuy Synthes Products Incorporated (Johnson & Johnson)
• Original Assignee: Ethicon Incorporated (Johnson & Johnson)
• Inventors: Kramer, Brian C., Gosiewska, Anna, Brown, Laura J., Kihm, Anthony J.
• Application Number:
  US12/337,439
• Publication Number:
  US 20090169597A1
• Time in Patent Office: Days
• US Class Current: 424/423
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61P 19/04 for non-specific disorders of the connective tissue
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly

Abstract

Methods for treating a patient having a disease or condition related to IVD degeneration are provided. The methods comprise administering cells obtained from human umbilical cord tissue, or administering pharmaceutical compositions comprising such cells or prepared from such cells. In some embodiments, administering the cells promotes repair and regeneration of degenerated IVD tissue in the patient. Pharmaceutical compositions for use in the inventive methods, as well as kits for practicing the methods are also provided.

Claims

1. A method of treating a disease or condition related to intervertebral disc degeneration, comprising administering cells obtained from human umbilical cord tissue to an intervertebral disc in an amount effective to treat the disease or condition, wherein the umbilical cord tissue is substantially free of blood, and wherein the cells:

are capable of self-renewal and expansion in culture and have the potential to differentiate;

require L-valine for growth;

can grow in at least about 5% oxygen.

2. The method of claim 1, wherein the cells have at least of the following characteristics:

a) express oxidized low density lipoprotein receptor 1, reticulon, chemokine receptor ligand 3, and/or granulocyte chemotactic protein 2;

b) do not produce CD117, HLA-DR or telomerase;

c) express alpha smooth muscle actin; and

d) express, relative to a human fibroblast, mesenchymal stem cell, or iliac crest bone marrow cell, increased levels of oxidized low density lipoprotein receptor 1, interleukin 8, or reticulon 1.

3. The method of claim 1, wherein the cells express CD10, CD13, CD44, CD73, and CD90.

4. The method of claim 1, wherein the cells are administered by injection.

5. The method of claim 1, wherein the cells are administered encapsulated within an implantable device.

6. The method of claim 1, wherein the cells are administered by implantation of a matrix comprising the cells.

7. The method of claim 1, wherein the cells are administered with at least one other cell type.

8. The method of claim 7, wherein the at least one other cell type is administered simultaneously with, or before, or after, the cells obtained from human umbilical cord tissue.

9. The method of claim 7, wherein the at least one other cell type is engineered to express at least one exogenous gene product.

10. The method of claim 9, wherein the exogenous gene product is a trophic factor.

11. The method of claim 9, wherein the exogenous gene product modulates expression of one or more extracellular matrix proteins.

12. The method of claim 1, wherein the cells are administered with at least one agent.

13. The method of claim 12, wherein the at least one agent is administered simultaneously with, before, or after administration of the cells obtained from human umbilical cord tissue.

14. The method of claim 12, wherein the at least one agent is a trophic factor.

15. The method of claim 14, wherein the trophic factor is selected from the group consisting of:

TGF-beta, GDF-5, PDGF-BB and TIMP1.

16. The method of claim 14 wherein the trophic factor exerts a trophic effect on the cells obtained from human umbilical cord tissue.

17. The method of claim 16 wherein the trophic effect comprises increasing expression of one or more extracellular matrix proteins.

18. The method of claim 1, wherein the cells are administered into a degenerated intervertebral disc.

19. The method of claim 18 wherein the cells are administered into the nucleus pulposus of the intervertebral disc.

20. The method of claim 18 wherein the cells are administered into the annulus fibrosus of the intervertebral disc.

21. The method of claim 1, wherein the cells are engineered to express at least one exogenous gene product.

22. The method of claim 21, wherein exogenous gene product is a trophic factor.

23. The method of claim 21, wherein the exogenous gene product modulates expression of one or more extracellular matrix proteins.

24. The method of claim 1, wherein the umbilical cord tissue-derived cells have the ability to differentiate into cells displaying a nucleus pulposus cell phenotype.

25. The method of claim 1, wherein the umbilical cord tissue-derived cells have the ability to differentiate into cells displaying an annulus fibrosus cell phenotype.

26. The method of claim 1, further comprising inducing the cells obtained from human umbilical cord tissue to at least partially differentiate in vitro.

27. The method of claim 26, wherein the cells are induced to differentiate into cells displaying an annulus fibrosus cell phenotype.

28. The method of claim 26, wherein the cells are induced to differentiate into cells displaying a nucleus pulposus cell phenotype.